- Home
- EDD vs SLP Comparison
EDD vs SLP Comparison
Compare EDD & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDD | SLP |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | 213 |
| Industry | Finance Companies | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.1M | 370.7M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | EDD | SLP |
|---|---|---|
| Price | $5.77 | $18.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 594.6K | 577.8K |
| Earning Date | 01-01-0001 | 04-09-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | N/A | $5.90 |
| P/E Ratio | ★ N/A | $42.63 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $4.96 | $11.09 |
| 52 Week High | $6.18 | $21.01 |
Technical Indicators
Market Signals| Indicator | EDD | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 65.07 |
| Support Level | $5.72 | $17.74 |
| Resistance Level | $6.03 | $18.57 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 28.99 | 64.58 |
Price Performance
Historical ComparisonAbout EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.